EntryPoint Capital LLC Takes Position in MiMedx Group, Inc. (NASDAQ:MDXG)

EntryPoint Capital LLC bought a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 49,093 shares of the company’s stock, valued at approximately $472,000.

Other large investors also recently added to or reduced their stakes in the company. Geode Capital Management LLC grew its stake in shares of MiMedx Group by 1.6% during the third quarter. Geode Capital Management LLC now owns 2,794,358 shares of the company’s stock valued at $16,518,000 after buying an additional 44,254 shares during the last quarter. Charles Schwab Investment Management Inc. grew its position in MiMedx Group by 6.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,435,397 shares of the company’s stock worth $8,483,000 after acquiring an additional 92,726 shares during the last quarter. Bank of New York Mellon Corp increased its stake in MiMedx Group by 0.7% in the 4th quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company’s stock worth $4,849,000 after purchasing an additional 3,300 shares during the period. Disciplined Growth Investors Inc. MN lifted its position in MiMedx Group by 0.8% in the third quarter. Disciplined Growth Investors Inc. MN now owns 355,387 shares of the company’s stock valued at $2,100,000 after purchasing an additional 2,737 shares during the last quarter. Finally, Wellington Management Group LLP boosted its stake in shares of MiMedx Group by 11.8% during the third quarter. Wellington Management Group LLP now owns 317,274 shares of the company’s stock valued at $1,875,000 after purchasing an additional 33,461 shares during the period. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Trading Down 2.5 %

MDXG opened at $7.90 on Wednesday. MiMedx Group, Inc. has a one year low of $5.47 and a one year high of $10.14. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53. The business has a 50 day simple moving average of $8.35 and a two-hundred day simple moving average of $7.89. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of 14.36 and a beta of 1.97.

MiMedx Group (NASDAQ:MDXG) last announced its earnings results on Wednesday, February 26th. The company reported $0.07 EPS for the quarter, meeting analysts’ consensus estimates of $0.07. The company had revenue of $92.91 million during the quarter, compared to the consensus estimate of $89.42 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. Analysts predict that MiMedx Group, Inc. will post 0.3 EPS for the current year.

Insider Transactions at MiMedx Group

In related news, insider Kimberly Maersk-Moller sold 4,106 shares of MiMedx Group stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $7.89, for a total transaction of $32,396.34. Following the sale, the insider now directly owns 310,836 shares in the company, valued at $2,452,496.04. The trade was a 1.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO William Frank Iv Hulse sold 81,446 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the sale, the chief accounting officer now directly owns 494,774 shares in the company, valued at $3,859,237.20. This represents a 14.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 144,018 shares of company stock valued at $1,130,312. Company insiders own 1.30% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $13.00 target price on shares of MiMedx Group in a research note on Thursday, February 27th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.